Partnerships in AML Diagnosis Foundation Medicine has established partnerships with Syndax Pharmaceuticals for developing tools to identify acute myeloid leukemia patients. This collaboration presents an opportunity for co-promotion or bundled offerings targeting healthcare institutions focusing on AML treatments.

Companion Diagnostics Development Foundation Medicine is working on a companion diagnostic tool for Merus N.V.'s bispecific antibody zenocutuzumab, targeting NRG1+ cancer. This initiative opens doors for partnerships with pharmaceutical companies seeking advanced diagnostic solutions in precision medicine.

Investment in Oncology Services Foundation Medicine recently invested $60,000 in Cancer Support Community to provide oncology services to cancer patients and their families. This philanthropic effort not only enhances brand reputation but also creates opportunities for collaborations with organizations focusing on cancer care and support.

RNA Platform Collaboration Collaborating with Merus N.V., Foundation Medicine is developing an RNA platform for NRG1 fusion-driven tumors. This project sets the stage for potential partnerships with biotech firms interested in leveraging genomic profiling for innovative cancer treatments.

Market Expansion Strategy With a revenue range of $100M - 1B, Foundation Medicine exhibits financial stability and growth potential. Sales teams can explore partnerships for global market expansion, targeting regions where precision oncology and personalized medicine are gaining traction.